蓝舌病病毒17型VP2蛋白单克隆抗体的制备及其抗原表位的鉴定

为制备蓝舌病病毒(BTV)血清17型VP2蛋白的单克隆抗体(MAb)及鉴定其抗原表位,本研究用原核表达系统部分重叠表达的两段VP2蛋白共同免疫BALB/c小鼠,采用细胞融合技术获得杂交瘤细胞,通过以重组VP2蛋为白包被抗原的间接ELISA筛选获得2株稳定分泌抗BTV17 VP2蛋白的MAbs杂交瘤细胞株,分别命名为3F4和4H10.Ig亚类鉴定2株MAbs均为IgG1/k链.Western blot证明,2株MAbs均能识别重组VP2蛋白.间接免疫荧光试验表明:2株MAbs均与BTV17呈阳性反应,其中MAb 3F4与BTV1、BTV2、BTV3、BTV5、BTV8、BTV11、BTV13、BTV16、BTV23、茨城病病毒(IBAV)、牛轮状病毒(BRV)、牛呼肠孤病毒(RV)均呈阴性反应,但与BTV10和BTV24呈弱阳性反应.利用合成多肽对VP2抗原表位鉴定结果表明,MAb 3F4识别的抗原表位为540DPWNNR545,MAb 4H10识别的抗原表位为540DPWNNRA546.本研究结果为建立BTV17型特异性检测方法及VP2功能研究奠定了基础.     

4型蓝舌病病毒VP2单克隆抗体抗原表位的鉴定

为鉴定蓝舌病病毒(BTV)的单克隆抗体(MAb)所识别的VP2蛋白竞争抑制型特异性抗原表位,本研究采用噬菌体展示技术对BTV VP2蛋白抗原表位氨基酸进行筛选。经过3轮淘选后进行测序,测序结果经分析比对后获得共同的短肽序列为~(160)NH~(161)。~(160)NH~(161)与已有的单抗杂交瘤细胞4A-1G7上清、腹水均发生特异性反应,并且~(160)NH~(161)与4型BTV阳性标准血清反应良好。本研究结果为4型BTV检测方法的建立及VP2蛋白结构和功能的研究奠定了基础。     

25型蓝舌病病毒VP2蛋白的原核表达及鉴定

为获得体外表达的25型蓝舌病病毒(BTV)VP2蛋白,本研究以NCBI上发表的25型BTV L2基因序列为模版,设计3对引物,PCR扩增3段部分重叠基因。将3段基因克隆到原核表达载体p ET-28a(+)中,构建重组质粒。以1.0 mmol/L的IPTG诱导含有阳性质粒的重组菌p ET-28a(+)-VP2-A/BL21、p ET-28a(+)-VP2-B/BL21、p ET-28a(+)-VP2-C/BL21进行表达,获得3段VP2蛋白,分别命名为VP2-A、VP2-B、VP2-C。经SDS-PAGE鉴定结果表明,重组蛋白以包涵体形式表达,大小依次为50 ku、48 ku、48 ku,与预期蛋白大小一致。经Western blot分析,VP2-A、VP2-B、VP2-C与His-Tag单抗发生特异性结合,证明其具有较好的反应原性。25型蓝舌病病毒VP2蛋白的分段表达为VP2蛋白的功能研究和制备蓝舌病的诊断试剂奠定了基础。     

A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep

An outbreak of bluetongue caused by bluetongue virus serotype 2 virus in certain Mediterranean countries during 1999/2000, presented an opportunity to produce a monovalent type 2 vaccine. Since no data have been published previously on the protection conferred by the current live attenuated bluetongue vaccine strains used in the polyvalent vaccine, a challenge experiment was performed to determine the degree of homologous protection induced by the type 2 vaccine strain. The standard vaccine dose of 5 x 10(4) pfu of vaccine conferred 99.7% protection against clinical disease and no viraemia was detected in the vaccinates.     

Clinical pathology of Australian bluetongue virus serotype 16 infection in Merino sheep

SUMMARY Viraemic blood from an ox naturally infected with Australian bluetongue (BLU) virus serotype 16 was passaged twice in sheep. Twelve 2- to 4-years-old Merino ewes, negative in a bluetongue agar gel Immunodiffusion test, were Inoculated with viraemic blood from the second sheep passage. They were examined for 18 days and compared with a control group. Significant changes in haematological measurements, namely packed cell volume, total white cell count and lymphocyte count, and in plasma enzyme concentrations, namely aspartate transaminase and creatine kinase, occurred in the infected sheep. All Infected sheep became sick. The antibody response, and clinical and necropsy findings were consistent with other reports of mild to moderate disease with Australian BLU serotypes.     

Experimental infection of South American camelids with bluetongue virus serotype 8

Bluetongue (BT) is an infectious, non-contagious disease of wild and domestic ruminants. It is caused by bluetongue virus (BTV) and transmitted by Culicoides biting midges. Since 1998, BT has been emerging throughout Europe, threatening not only the na?ve ruminant population. Historically, South American camelids (SAC) were considered to be resistant to BT disease. However, recent fatalities related to BTV in captive SAC have raised questions about their role in BTV epidemiology. Data on the susceptibility of SAC to experimental infection with BTV serotype 8 (BTV-8) were collected in an animal experiment. Three alpacas (Vicugna pacos) and three llamas (Lama glama) were experimentally infected with BTV-8. They displayed very mild clinical signs. Seroconversion was first measured 6-8 days after infection (dpi) by ELISA, and neutralising antibodies appeared 10-13 dpi. BTV-8 RNA levels in blood were very low, and quickly cleared after seroconversion. However, spleens collected post-mortem were still positive for BTV RNA, over 71 days after the last detection in blood samples. Virus isolation was only possible from blood samples of two alpacas by inoculation of highly sensitive interferon alpha/beta receptor-deficient (IFNAR(-/-)) mice. An in vitro experiment demonstrated that significantly lower amounts of BTV-8 adsorb to SAC blood cells than to bovine blood cells. Although this experiment showed that SAC are generally susceptible to a BTV-8 infection, it indicates that these species play a negligible role in BTV epidemiology.     

Bluetongue disease in Swiss sheep breeds: clinical signs after experimental infection with bluetongue virus serotype 8

Clinical disease of bluetongue (BT) in sheep may differ depending on breed, age and immunity of infected sheep and may also vary between serotype and strain of BT virus (BTV). Since there are no data available on the susceptibility of Swiss sheep breeds for BT, we performed experimental infection of the 4 most common Swiss sheep breeds and the highly susceptible Poll Dorset sheep with the BTV serotype 8 (BTV-8) circulating in Northern Europe since 2006. Clinical signs were assessed regarding severity, localisation, progression and time point of their appearance. The results clearly show that the Swiss sheep breeds investigated were susceptible to BTV-8 infection. They developed moderate, BT-characteristic symptoms, which were similar to those observed in Poll Dorset sheep. Regardless of breed, the majority of infected animals showed fever, swelling of the head as well as erosions of the mouth and subcutaneous haemorrhages.     

表达A型口蹄疫病毒衣壳蛋白重组腺病毒的构建

为构建表达A型口蹄疫病毒(FMDV)衣壳蛋白的重组腺病毒,本研究通过人工合成A型FMDVP1-2A、2B和3C融合基因,将其克隆到腺病毒穿梭载体pShuttle-CMV中,利用E.coli BJ5183内同源重组将目的基因插入腺病毒骨架质粒pAdEasy-1中,获得携带A型FMDV P1-2A-2B-3C基因的重组AdEasy-1。该重组质粒经PacⅠ线性化后转染AD-293细胞,获得重组腺病毒rAd-A09。经PCR检测,该重组腺病毒在传代过程中目的基因稳定存在,病毒滴度在第8代时可达到108.5TCID50/mL。间接免疫荧光检测和western blot分析表明,rAd-A09在AD-293细胞中产生FMDV的结构蛋白VP0、VP1和VP3。该重组腺病毒的构建为口蹄疫新型疫苗的研究奠定了基础。     

An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy

Because no suitable products are at the moment available to safely control the spread of BTV-16 in Europe, an inactivated vaccine was produced from the reference field isolate of bluetongue virus serotype 16. One group of six sheep was vaccinated subcutaneously with the inactivated vaccine twice, on days 0 and 28, whereas a second group of eight sheep was inoculated with saline solution and used as mock-vaccinated control animals. Seventy-eight days after the first vaccination, all sheep were inoculated subcutaneously with a suspension containing 10(6.3) TCID(50) of a virulent reference BTV-16 isolate. Apart from a transient inflammatory reaction at the injection site, no adverse effects were reported following vaccination. All vaccinated animals developed high titres (7.3-9.3log(2)(ED50%/50 microl)) of virus-specific neutralising antibodies and were resistant to challenge with BTV-16. Conversely, following challenge, control animals developed hyperthermia and long lasting high-titre viraemia.     

Cloning and expression of the M5 RNA segment encoding outer capsid VP5 of epizootic hemorrhagic disease virus Japan serotype 2, Ibaraki virus

The complete nucleotide sequence of a cDNA clone representing the M5 RNA segment of epizootic hemorrhagic disease virus Japan serotype 2 (EHDV-2), Ibaraki virus, was determined. The M5 segment is 1641 base pairs long with the single open reading frame which predicts a polypeptide of 527 amino acids. The comparison of the amino acid sequence of the VP5 with those of EHDV-1, bluetongue virus serotype 10, and African horse sickness virus serotype 4 revealed that the protein shared 67%, 57% and 42% homologies, respectively. In addition, the VP5 protein was expressed in insect cells by recombinant baculovirus, which could be recognized by the mouse anti-EHDV-2 sera at a position of the expected 59 kDa on immunoblot analysis.     

Susceptibility of in vitro produced hatched bovine blastocysts to infection with bluetongue virus serotype 8

ABSTRACT: Bluetongue virus serotype 8 (BTV-8), which caused an epidemic in ruminants in central Western Europe in 2006 and 2007, seems to differ from other bluetongue serotypes in that it can spread transplacentally and has been associated with an increased incidence of abortion and other reproductive problems. For these reasons, and also because BTV-8 is threatening to spread to other parts of the world, there is a need for more information on the consequences of infection during pregnancy. The aim of the present study was to investigate whether hatched (i.e. zona pellucida-free) in vitro produced bovine blastocysts at 8-9 days post insemination are susceptible to BTV-8 and whether such infection induces cell death as indicated by apoptosis. Exposure of hatched in vitro produced bovine blastocysts for 1 h to a medium containing 103.8 or 104.9 TCID50 of the virus resulted in active viral replication in between 25 and 100% of the cells at 72 h post exposure. The infected blastocysts also showed growth arrest as evidenced by lower total cell numbers and a significant level of cellular apoptosis. We conclude from this in vitro study that some of the reproductive problems that are reported when cattle herds are infected with BTV-8 may be attributed to direct infection of blastocysts and other early-stage embryos in utero.     

Transplacental and oral transmission of wild-type bluetongue virus serotype 8 in cattle after experimental infection

Potential vertical transmission of wild-type bluetongue virus serotype 8 (BTV-8) in cattle was explored in this experiment. We demonstrated transplacental transmission of wild-type BTV-8 in one calf and oral infection with BTV-8 in another calf. Following the experimental BTV-8 infection of seven out of fifteen multi-parous cows eight months in gestation, each newborn calf was tested prior to colostrum intake for transplacental transmission of BTV by RRT-PCR. If transplacental transmission was not established the calves were fed colostrum from infected dams or colostrum from non-infected dams spiked with BTV-8 containing blood. One calf from an infected dam was born RRT-PCR positive and BTV-specific antibody (Abs) negative, BTV was isolated from its blood. It was born with clinical signs resembling bluetongue and lived for two days. Its post-mortem tissue suspensions were RRT-PCR positive. Of the seven calves fed colostrum from infected dams, none became infected. Of the six calves fed colostrum from non-infected dams spiked with infected blood, one calf became PCR-positive at day 8 post-partum (dpp), seroconverted 27 days later, and remained RRT-PCR and Abs positive for the duration of the experiment (i.e., 70 dpp). This work demonstrates that transplacental transmission in late gestation and oral infection of the neonate with wild-type BTV-8 is possible in cattle under experimental conditions.     

蓝舌病毒8型VP7蛋白的表达及其单克隆抗体的制备

对蓝舌病毒(BTV)8型群特异性抗原VP7蛋白进行了原核表达,制备了单克隆抗体(McA b),并分析其特性。将BTV 8型VP7蛋白基因分别克隆至p ET-28a-c(+)和p MAL-c5x载体中,在大肠杆菌中诱导表达分别带组氨酸标签(His)和麦芽糖结合蛋白(MBP)标签的的融合蛋白His-VP7和MBP-VP7。用纯化的His-VP7免疫BALB/c小鼠制备McA b,以MBP-VP7为包被抗原筛选分泌McA b的杂交瘤细胞。筛选出的1株抗BTV的McA b命名为3F4,亚类鉴定为IgG 1型;该单抗既能与重组BTV VP7蛋白发生反应,又能识别BTV,为BTV的血清学检测提供了工具。     

Epidemiology of bluetongue virus serotype 8 outbreaks in the Netherlands in 2006

In August 2006 a major epidemic of Bluetongue (BT) occurred in north-western Europe, affecting The Netherlands, Belgium, Germany, Luxemburg, and the north of France. It was caused by Br virus serotype 8 (BTV-8), a serotype previously unknown to the EU. Although clinical disease is usually restricted to sheep, this virus also caused clinical disease in a small proportion of cattle. The last clinical outbreak of BT in The Netherlands occurred mid-December 2006. The delay between observation of the first clinical signs by the owner and reporting of a clinically suspect BT situation to the veterinary authorities was approximately 2 weeks. BTV-8-associated clinical signs were more prominent in sheep than in cattle, and the relative frequency of specific clinical signs was different in cattle and sheep. Morbidity and mortality rates were significantly higher among sheep than among cattle, and a higher proportion of cattle than sheep recovered from clinical disease.     

Study of protection by recombinant fowl poxvirus expressing C-terminal nucleocapsid protein of infectious bronchitis virus against challenge.

A stable recombinant fowl poxvirus (rFPV) expressing the C-terminal region (119 amino acids) of the nucleocapsid (N) protein of an infectious bronchitis virus (IBV) strain Ch3 was constructed by inserting the coding sequence within the thymidine kinase gene of fowl poxvirus (FPV) by homologous recombination. The N protein was expressed under control of the vaccinia virus promoter P7.5 in chicken embryo fibroblast cell cultures as seen in immunofluorescence assay and in rFPV-inoculated specific-pathogen-free (SPF) chickens by detecting antibodies with enzyme-linked immunosorbent assay (ELISA). A homologous IBV strain (Ch3) and two heterologous IBV strains (Ch5 and H4) were used to inoculate SPF chickens in a challenge to examine the protective efficacy of the rFPV. When the chickens were challenged with IBV Ch3 or Ch5, the control birds had respiratory signs of infections bronchitis, whereas all the vaccinated birds were clinically normal although low levels of the IBV infection were detected by a differential ELISA. In contrast, in the chickens challenged with IBV H4, all control birds and vaccinated birds suffered from the highly lethal IBV H4 infection. Our results suggest that the C-terminal 119 amino acid of the nucleocapsid expressed by FPV is a host-protective antigen and may induce cross-protective immunity against illness among some IBV strains.     

Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8

Bluetongue (BT) is an economically important disease of ruminants caused by bluetongue virus (BTV) and transmitted by Culicoides biting midges. The most practical and effective way to protect susceptible animals against BTV is by vaccination. Data from challenge studies in calves and sheep conducted by Intervet International b.v., in particular, presence of viral RNA in the blood of challenged animals, were used to estimate vaccine efficacy. The results of the challenge studies for calves indicated that vaccination is likely to reduce the basic reproduction number (R(0)) for BTV in cattle to below one (i.e. prevent major outbreaks within a holding) and that this reduction is robust to uncertainty in the model parameters. Sensitivity analysis showed that the whether or not vaccination is predicted to reduce R(0) to below one depended on the following assumptions: (i) whether "doubtful" results from the challenge studies are treated as negative or positive; (ii) whether or not the probability of transmission from host to vector is reduced by vaccination; and (iii) whether the extrinsic incubation period follows a realistic gamma distribution or the more commonly used exponential distribution. For sheep, all but one of the vaccinated animals were protected and, consequently, vaccination will consistently reduce R(0) in sheep to below one. Using a stochastic spatial model for the spread of BTV in Great Britain (GB), vaccination was predicted to reduce both the incidence of disease and spatial spread in simulated BTV outbreaks in GB, in both reactive vaccination strategies and when an incursion occurred into a previously vaccinated population.     

猪圆环病毒2型Cap蛋白与猪O型口蹄疫病毒VP1蛋白在杆状病毒中共表达及鉴定

为在真核细胞中共表达猪圆环病毒2型(PCV2)Cap蛋白与猪O型口蹄疫病毒(FMDV)VP1蛋白,本研究将其各自编码基因克隆于杆状病毒双表达载体(pFastBacTMDual)中构建重组转移质粒(pFBD-Cap-VP1),转化至DH10BacTM感受态细胞中制备重组杆粒(rBacmid-Cap-VP1),并转染Sf21昆虫细胞,拯救出能够共表达PCV2-Cap和FMDV-VP1蛋白的重组杆状病毒(rBac-Cap-VP1)。SDS-PAGE和western blot检测结果表明,共表达的重组PCV2-Cap和FMDV-VP1蛋白产物的分子量分别为28 ku和30 ku,各占总蛋白含量的11.6%和3.4%,能够分别与PCV2和FMDV抗体发生特异性反应,表明共表达蛋白具有良好的反应原性。本研究为PCV2和FMDV基因工程二联亚单位疫苗的研制奠定了基础。